The LEAD clinical trials, which began in 2006 and included thousands of participants worldwide, demonstrated liraglutides ability to improve glycemic control and promote weight loss (35)
Newer agents such as tirzepatide (a dual GIP/GLP-1 receptor agonist) may offer different tolerability profiles, though gastrointestinal effects remain common and availability on the NHS may be limited pending NICE appraisal and local commissioning decisions
Overall, GLP-1 receptor agonists may be useful for selected patients with obesity-related KOA, but their use requires careful patient selection, dose titration, adverse-event monitoring, nutritional and functional support, perioperative coordination, and realistic planning for long-term adherence
Heres How It Works Testimonials See what some of our patients have said about their weight loss journey with Oahu Weight Loss
however, there is little data regarding glucagon-like peptide-1 receptor agonist in overdose
Sermorelin has prior FDA approval history